CDEK
← All drugs Report issue

triprizumab

mAbexperimental

Clinical trial activity

39 trials · 26 clinical orgs · 0 marketing orgs

Phase 1
14
Phase 2
30
Phase 3
7
Phase 4
0

Earliest trial started Apr 6, 2017 (NCT03167853)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07151560Phase 2Aug 30, 2025Wuhan University
NCT06712888Phase 3Jan 1, 2025Central South University, Chinese Academy of Medical Sciences, Fujian Medical University, Guangdong Medical University, Guangxi Medical University, Hacettepe University, Sun Yat-Sen University, The University of Hong Kong, University of Electronic Science and Technology of China
NCT06571422Phase 1Oct 23, 2024Shanghai Junshi Bioscience Co.,Ltd., Sponsor GmbH
NCT06587802Phase 2Sep 30, 2024Sun Yat-Sen University
NCT06505837Phase 3Jul 11, 2024Innovaderm, Shanghai Junshi Bioscience Co.,Ltd., Sponsor GmbH
NCT06370754Phase 1/Phase 2 (Phase 2)Apr 30, 2024Fudan University
NCT06227117Phase 2Jul 27, 2023RemeGen
NCT05804526Phase 1/Phase 2 (Phase 2)Jul 19, 2023RemeGen
NCT05842018Phase 2May 1, 2023Tianjin Medical University
NCT05917158Phase 2Nov 23, 2022Jinlin University
NCT05297552Phase 2Jul 1, 2022Peking University, RemeGen
NCT05262842Phase 1Mar 29, 2022Shanghai Junshi Bioscience Co.,Ltd., Sponsor GmbH, Sun Yat-Sen University
NCT04991506Phase 1Oct 15, 2021Elpiscience Biopharma, Ltd., Shanghai Junshi Bioscience Co.,Ltd.
NCT05016973Phase 2Oct 1, 2021Nanjing University
NCT05274438Phase 2Jan 26, 2021Peking University
NCT05173246Phase 2Nov 17, 2020Shanghai Junshi Bioscience Co.,Ltd., Sun Yat-Sen University, Yiling Pharmaceutical Inc.
NCT04523883Phase 2Aug 10, 2020Central South University, Fudan University, Fujian Medical University, Guizhou Medical University, Jiao Tong University, Tianjin Medical University
NCT04280341Phase 1Mar 31, 2020Peking University, RemeGen
NCT04264936Phase 1/Phase 2 (Phase 2)Feb 15, 2020Chinese Academy of Medical Sciences
NCT04250948Phase 2Oct 12, 2019Shanghai Junshi Bioscience Co.,Ltd., Sun Yat-Sen University
Showing 20 of 39 trials
Page 1 / 2

Organizations

Research & Development (26)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Shanghai Junshi Bioscience Co.,Ltd.For profit12532017
Sun Yat-Sen UniversityAcademic/Hospital9832018
Chinese Academy of Medical SciencesAcademic/Hospital8432018
Fudan UniversityAcademic/Hospital5322017
Peking UniversityAcademic/Hospital5422017
RemeGenFor profit4322020
AnewPharmaFor profit3312018
Central South UniversityAcademic/Hospital3122019
Sponsor GmbHAcademic/Hospital3022022
Fujian Medical UniversityAcademic/Hospital2022020
Tianjin Medical UniversityAcademic/Hospital2112020
Baylor UniversityAcademic/Hospital1112019
Elpiscience Biopharma, Ltd.For profit1112021
Guangdong Medical UniversityAcademic/Hospital1012025
Guangxi Medical UniversityAcademic/Hospital1012025
Guizhou Medical UniversityAcademic/Hospital1012020
Hacettepe UniversityAcademic/Hospital1012025
InnovadermFor profit1012024
Jiao Tong UniversityAcademic/Hospital1112020
Jinlin UniversityAcademic/Hospital1112022
26 organizations
Page 1 / 2